Journal of Applied Physiology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

J Appl Physiol 102: 814-816, 2007. First published October 26, 2006; doi:10.1152/japplphysiol.01208.2006
8750-7587/07 $8.00
This Article
Right arrow Full Text (PDF) Free
Right arrow All Versions of this Article:
102/2/814    most recent
01208.2006v1
Right arrow Submit a response
Right arrow View responses
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (9)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Pedersen, B. K.
Right arrow Articles by Mooney, R. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pedersen, B. K.
Right arrow Articles by Mooney, R. A.

POINT-COUNTERPOINT

Interleukin-6 does/does not have a beneficial role in insulin sensitivity and glucose homeostasis

Bente K. Pedersen

The Centre of Inflammation and Metabolism
Department of Infectious Diseases
Copenhagen Muscle Research Centre, Rigshospitalet
The Faculty of Health Sciences
University of Copenhagen
Copenhagen, Denmark
e-mail: bkp{at}rh.dk

Mark A. Febbraio

Cellular and Molecular Metabolism Laboratory
Baker Heart Research Institute
Department of Biochemistry and Molecular Biology
Monash University
Melbourne, Australia
e-mail: mark.febbraio{at}baker.edu.au

POINT: INTERLEUKIN-6 DOES HAVE A BENEFICIAL ROLE IN INSULIN SENSITIVITY AND GLUCOSE HOMEOSTASIS

Growing evidence links Type 2 diabetes to a state of low-grade chronic inflammation, and it has been suggested that interleukin (IL)-6 promotes insulin resistance due to the observation that plasma IL-6 is often elevated in patients with metabolic disease. However, it is now well known that IL-6 is rapidly released into the circulation following exercise (8) and, from a simplistic physiological point of view, it seems paradoxical that working muscle would release a factor that inhibits insulin signaling when insulin action is enhanced in the immediate postexercise period (30). The idea of IL-6 being a bad guy with regard to metabolic actions is primarily based on 1) correlational relationships in cohort studies; 2) animal studies, neglecting that mouse and human IL-6 exhibit only ~42% sequence identity, and 3) in vitro cell culture studies of supraphysiological concentrations of IL-6. In this review, we challenge the generally held view that IL-6 is a bad guy based on recent carefully conducted experiments in both in vitro and, importantly, humans in vivo.

The in vivo effect of IL-6 on glucose and lipid metabolism.   Although IL-6 appears to play a role in endogenous glucose production (EGP) during exercise in humans, its action on the liver is dependent on a yet unidentified muscle contraction-induced factor (7). In healthy humans in the basal condition, acute rhIL-6 administration at physiological concentrations does not impair whole body glucose disposal, net leg glucose uptake, nor does it increase endogenous glucose production (14, 17, 23). In patients with Type 2 diabetes, rhIL-6 decreases circulating insulin, suggesting an insulin-sensitizing effect of IL-6 (17). To test this hypothesis, we recently demonstrated that IL-6 increased glucose infusion rate and glucose oxidation without affecting the suppression of endogenous glucose production during a hyperinsulinemic euglycemic clamp in healthy humans (4). These data are in contrast with observations reported in mice (11). The finding of an insulin-sensitizing effect of IL-6 at conditions where EGP was completely suppressed underlines that in humans, the main effects of IL-6 with regard to glucose metabolism are likely to be in peripheral tissues (muscle, adipose), whereas IL-6 does not influence glucose output from the liver.

Infusion of rhIL-6 into healthy humans to obtain physiological concentrations of IL-6 increased lipolysis in the absence of hypertriacylglyceridemia or changes in catecholamines, glucagon, insulin, or any adverse effects in healthy individuals (14, 17, 25) and in patients with Type 2 diabetes (17). These findings, together with cell culture experiments demonstrating that IL-6 alone markedly increases both lipolysis and fat oxidation, identify IL-6 as a novel lipolytic factor (17). Interestingly, Axokine, a human variant of the IL-6 family cytokine member ciliary neurotrophic factor (CNTF), which acts via a common receptor with IL-6 (the IL-6R/LIFR/ CNTFR/gp130 receptor complex), induces marked weight loss in obese patients (6). Moreover, blocking IL-6 in clinical trials with patients with rheumatoid arthritis leads to enhanced cholesterol and plasma glucose levels, indicating that functional lack of IL-6 may lead to insulin resistance and an atherogenic lipid profile (1, 5, 15). In accordance, IL-6 knockout mice develop late onset obesity and impaired glucose tolerance (26). Together, these studies add weight to the notion that IL-6 family cytokines are "anti-obesogenic."

Mechanisms of action.   In isolated hepatocytes and in mice in vivo, IL-6 has a negative effect on hepatic insulin sensitivity. These findings are without clinical relevance as in vivo studies in humans clearly demonstrate that neither splanchnic glucose output measured by a-v balance across the hepatosplanchnic tissue nor isotopic tracer determined endogenous glucose production is increased by acute infusion of rhIL-6 (14, 17, 23). In vitro, IL-6 either enhances (4, 24) or does not enhance (13, 20) glucose transport in adipocytes. The fact that IL-6 infusion increases subcutaneous adipose tissue glucose uptake in humans (14) argues against IL-6 as an insulin resistance-inducing agent in adipocytes. In addition, several studies reported that IL-6 increases intramyocellular or whole body fatty acid oxidation, which is likely to decrease intramyocellular fatty acid accumulation, which can impair insulin signaling (reviewed in Ref. 4). With regard to myocytes, IL-6 enhances insulin-stimulated glucose transport (4) and glycogen synthesis (28). In vivo, experiments demonstrated that IL-6 increases basal and insulin-stimulated glucose uptake via an increased GLUT4 translocation (4).

Recent evidence suggests a link between IL-6 and AMP-activated protein kinase (AMPK). AMPK activation stimulates fatty acid oxidation and increases glucose uptake (9). IL-6 was shown to enhance AMPK in both skeletal muscle and adipose tissue (10) and, more recently, the effects of IL-6 on enhanced glucose uptake in skeletal myotubes were abolished in cells infected with an AMPK-dominant negative construct (4). Studies have shown that IL-6 can enhance lipid oxidation in vitro (17), ex vivo (2), and in vivo (17, 25). AMPK phosphorylates ACC, resulting in inhibition of ACC activity, which in turn leads to a decrease in malonyl CoA content, relieving inhibition of CPT-1 and increasing fatty acid oxidation (9). We recently showed that the IL-6-mediated phosphorylation of ACC and subsequent palmitate oxidation is AMPK dependent (4). Our data, together with our recent findings regarding CNTF, which markedly enhances lipid oxidation via activation of AMPK (27), suggest that ligands that bind to the gp130 receptor complex can enhance glucose uptake and fat oxidation via activation of AMPK.

IL-6 has been shown to activate SOCS proteins in liver, leading to hepatic insulin resistance (21). IL-6 increased SOCS3 expression in myotubes, but concomitantly increased glucose uptake in these cells (4). While IL-6 increased SOCS3 twofold in muscle, it was increased ~25-fold in liver, suggesting that capacity for IL-6 to induce SOCS3 is much greater in hepatic tissue (29). The possibility exists that the negative effects of IL-6 on SOCS3 may be overridden by the positive effects on AMPK.

IL-6 stimulates the production of anti-inflammatory cytokines (16) and suppresses TNF-{alpha} production in humans (22). Direct evidence for a role of TNF in insulin resistance in humans has been obtained (19) and it is likely that muscle-derived IL-6 offers protection against TNF-induced insulin resistance (16).

If IL-6 is a good guy, why does it coexist with the bad guys?   Subjects with risk genotypes for both TNF-{alpha} (AA; A shows increased TNF transcription) and IL-6 (CC; C shows decreased transcription) have the highest incidence of diabetes (12), favoring the theory that high levels of TNF-{alpha} and low production of IL-6 are determining factors in the metabolic syndrome. High circulating levels of IL-6 may or may not be found in patients with Type 2 diabetes, but in general IL-6 is not elevated in lean subjects with insulin resistance (3, 18). Given the different biological profiles of TNF-{alpha} and IL-6 and given that TNF-{alpha} can trigger IL-6 release, one theory holds that it is adipose tissue-derived TNF-{alpha} that is actually the "driver" behind the metabolic syndrome and that increased systemic levels of IL-6 reflect locally produced TNF-{alpha} (16). Although IL-6 increases and TNF-{alpha} decreases insulin-stimulated glucose uptake in adipocytes, the addition of TNF-{alpha} to IL-6 totally abolishes the enhanced insulin action, highlighting the notion that it is TNF, not IL-6, that is the "bad guy" (Hage M et al., unpublished observations).

In summary, acute IL-6 administration to humans increases insulin-stimulated glucose disposal and fatty acid oxidation in vivo and IL-6 has strong anti-inflammatory effects. Activation of AMPK by IL-6 appears to play an important role in modulating some of these metabolic effects.

GRANTS

Support was obtained from the Danish Medical Research Foundation, and the Commission of the European Communities (Contract No. LSHM-CT-2004–005272 EXGENESIS). Studies conducted by M. A. Febbraio were supported by grants from the National Health and Medical Research Council (NHMRC Project Grant Nos. 251558, 342115, 392206). M. A. Febbraio is a Senior Research Fellow of the NHMRC.

ACKNOWLEDGMENTS

We thank the Centre of Inflammation and Metabolism (supported by Danish National Research Foundation Grant DG 02–512-555) and the Copenhagen Muscle Research Centre (supported by grants from the University of Copenhagen, the Faculties of Science and of Health Sciences at this university, and the Copenhagen Hospital Corporation).

REFERENCES

  1. Atlizumab: anti-IL6 receptor antibody-Chugai, anti-interleukin-6 receptor antibody-Chugai, MRA-Chugai. BioDrugs 17: 369–372, 2003.[CrossRef][ISI][Medline]
  2. Bruce CR, Dyck DJ. Cytokine regulation of skeletal muscle fatty acid metabolism: effect of interleukin-6 and tumor necrosis factor-alpha. Am J Physiol Endocrinol Metab 287: E616–E621, 2004.[Abstract/Free Full Text]
  3. Carey AL, Bruce CR, Sacchetti M, Anderson MJ, Olson D, Saltin B, Hawley JA, Febbraio MA. Interleukin-6 and tumor necrosis factor-alpha are not increased in patients with type 2 diabetes: evidence that plasma IL-6 is related to fat mass and not insulin responsiveness. Diabetologia 47: 1029–1037, 2004.[ISI][Medline]
  4. Carey AL, Steinberg GR, Macaulay SL, Thomas WG, Holmes AG, Ramm G, Prelovsek O, Hohnen-Behrens C, Watt MJ, James DE, Kemp BE, Pedersen BK, Febbraio MA. IL-6 increases insulin stimulated glucose disposal in humans and glucose uptake and fatty acid oxidation in vitro via AMPK. Diabetes 55: 2688–2697, 2006.[Abstract/Free Full Text]
  5. Choy EH, Isenberg DA, Garrood T, Farrow S, Ioannou Y, Bird H, Cheung N, Williams B, Hazleman B, Price R, Yoshizaki K, Nishimoto N, Kishimoto T, Panayi GS. Therapeutic benefit of blocking interleukin-6 activity with an anti-interleukin-6 receptor monoclonal antibody in rheumatoid arthritis: a randomized, double-blind, placebo-controlled, dose-escalation trial. Arthritis Rheum 46: 3143–3150, 2002.[CrossRef][ISI][Medline]
  6. Ettinger MP, Littlejohn TW, Schwartz SL, Weiss SR, McIlwain HH, Heymsfield SB, Bray GA, Roberts WG, Heyman ER, Stambler N, Heshka S, Vicary C, Guler HP. Recombinant variant of ciliary neurotrophic factor for weight loss in obese adults: a randomized, dose-ranging study. JAMA 289: 1826–1832, 2003.[Abstract/Free Full Text]
  7. Febbraio MA, Hiscock N, Sacchetti M, Fischer CP, Pedersen BK. Interleukin-6 is a novel factor mediating glucose homeostasis during skeletal muscle contraction. Diabetes 53: 1643–1648, 2004.[Abstract/Free Full Text]
  8. Febbraio MA, Pedersen BK. Muscle-derived interleukin-6: mechanisms for activation and possible biological roles. FASEB J 16: 1335–1347, 2002.[Abstract/Free Full Text]
  9. Kahn BB, Alquier T, Carling D, Hardie DG. AMP-activated protein kinase: ancient energy gauge provides clues to modern understanding of metabolism. Cell Metab 1: 15–25, 2005.[CrossRef][ISI][Medline]
  10. Kelly M, Keller C, Avilucea PR, Keller P, Luo Z, Xiang X, Giralt M, Hidalgo J, Saha AK, Pedersen BK. AMPK activity is diminished in tissues of the IL-6 knockout mice: the effect of exercise. Biochem Biophys Res Commun 320: 449–454, 2004.[CrossRef][ISI][Medline]
  11. Kim HJ, Higashimori T, Park SY, Choi H, Dong J, Kim YJ, Noh HL, Cho YR, Cline G, Kim YB, Kim JK. Differential effects of interleukin-6 and -10 on skeletal muscle and liver insulin action in vivo. Diabetes 53: 1060–1067, 2004.[Abstract/Free Full Text]
  12. Kubaszek A, Pihlajamaki J, Komarovski V, Lindi V, Lindstrom J, Eriksson J, Valle TT, Hamalainen H, Ilanne-Parikka P, Keinanen-Kiukaanniemi S, Tuomilehto J, Uusitupa M, Laakso M. Promoter polymorphisms of the TNF-alpha (G-308A) and IL-6 (C-174G) genes predict the conversion from impaired glucose tolerance to type 2 diabetes: the Finnish Diabetes Prevention Study. Diabetes 52: 1872–1876, 2003.[Abstract/Free Full Text]
  13. Lagathu C, Bastard JP, Auclair M, Maachi M, Capeau J, Caron M. Chronic interleukin-6 (IL-6) treatment increased IL-6 secretion and induced insulin resistance in adipocyte: prevention by rosiglitazone. Biochem Biophys Res Commun 311: 372–379, 2003.[CrossRef][ISI][Medline]
  14. Lyngso D, Simonsen L, Bulow J. Interleukin-6 production in human subcutaneous abdominal adipose tissue: the effect of exercise. J Physiol 543: 373–378, 2002.[Abstract/Free Full Text]
  15. Nishimoto N, Yoshizaki K, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T, Hashimoto J, Azuma J, Kishimoto T. Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trial. Arthritis Rheum 50: 1761–1769, 2004.[CrossRef][ISI][Medline]
  16. Petersen AM, Pedersen BK. The anti-inflammatory effect of exercise. J Appl Physiol 98: 1154–1162, 2005.[Abstract/Free Full Text]
  17. Petersen EW, Carey AL, Sacchetti M, Steinberg GR, Macaulay SL, Febbraio MA, and Pedersen BK. Acute IL-6 treatment increases fatty acid turnover in elderly humans in vivo and in tissue culture in vitro: evidence that IL-6 acts independently of lipolytic hormones. Am J Physiol Endocrinol Metab 288: E155–E162, 2005.[Abstract/Free Full Text]
  18. Petersen KF, Dufour S, Befroy D, Garcia R, Shulman GI. Impaired mitochondrial activity in the insulin-resistant offspring of patients with type 2 diabetes. N Engl J Med 350: 664–671, 2004.[Abstract/Free Full Text]
  19. Plomgaard P, Bouzakri K, Krogh-Madsen R, Zierath JR, Pedersen BK. TNF-alpha induces skeletal muscle insulin resistance in healthy human subjects via inhibition of AS160 phosphorylation. Diabetes 54: 2939–2945, 2005.[Abstract/Free Full Text]
  20. Rotter V, Nagaev I, Smith U. Interleukin-6 (IL-6) induces insulin resistance in 3T3–L1 adipocytes and is, like IL-8 and tumor necrosis factor-alpha, overexpressed in human fat cells from insulin-resistant subjects. J Biol Chem 278: 45777–45784, 2003.[Abstract/Free Full Text]
  21. Senn JJ, Klover PJ, Nowak IA, Zimmers TA, Koniaris LG, Furlanetto RW, Mooney RA. Suppressor of cytokine signaling-3 (SOCS-3), a potential mediator of interleukin-6-dependent insulin resistance in hepatocytes. J Biol Chem 278: 13740–13746, 2003.[Abstract/Free Full Text]
  22. Starkie R, Ostrowski SR, Jauffred S, Febbraio M, Pedersen BK. Exercise and IL-6 infusion inhibit endotoxin-induced TNF-alpha production in humans. FASEB J 17: 884–886, 2003.[Abstract/Free Full Text]
  23. Steensberg A, Fischer CP, Sacchetti M, Keller C, Osada T, Schjerling P, van Hall G, Febbraio MA, Pedersen BK. Acute interleukin-6 administration does not impair muscle glucose uptake or whole body glucose disposal in healthy humans. J Physiol 548: 631–638, 2003.[Abstract/Free Full Text]
  24. Stouthard JM, Oude Elferink RP, Sauerwein HP. Interleukin-6 enhances glucose transport in 3T3–L1 adipocytes. Biochem Biophys Res Commun 220: 241–245, 1996.[CrossRef][ISI][Medline]
  25. Van Hall G, Steensberg A, Sacchetti M, Fischer C, Keller C, Schjerling P, Hiscock N, Moller K, Saltin B, Febbraio MA, Pedersen BK. Interleukin-6 stimulates lipolysis and fat oxidation in humans. J Clin Endocrinol Metab 88: 3005–3010, 2003.[Abstract/Free Full Text]
  26. Wallenius V, Wallenius K, Ahren B, Rudling M, Carlsten H, Dickson SL, Ohlsson C, Jansson JO. Interleukin-6-deficient mice develop mature-onset obesity. Nat Med 8: 75–79, 2002.[CrossRef][ISI][Medline]
  27. Watt MJ, Dzamko N, Thomas WG, Rose-John S, Ernst M, Carling D, Kemp BE, Febbraio MA, Steinberg GR. CNTF reverses obesity-induced insulin resistance by activating skeletal muscle AMPK. Nat Med 12: 541–548, 2006.[CrossRef][ISI][Medline]
  28. Weigert C, Hennige AM, Brodbeck K, Haring HU, Schleicher ED. Interleukin-6 (IL-6) acts as insulin sensitizer on glycogen synthesis in human skeletal muscle cells by phosphorylation of Ser-473 of Akt. Am J Physiol Endocrinol Metab 289: E251–E257, 2005.[Abstract/Free Full Text]
  29. Weigert C, Hennige AM, Lehmann R, Brodbeck K, Baumgartner F, Schauble M, Haring HU, Schleicher ED. Direct cross-talk of interleukin-6 and insulin signal transduction via insulin receptor substrate-1 in skeletal muscle cells. J Biol Chem 281: 7060–7067, 2006.[Abstract/Free Full Text]
  30. Wojtaszewski JF, Jorgensen SB, Frosig C, Macdonald C, Birk JB, Richter EA. Insulin signalling: effects of prior exercise. Acta Physiol Scand 178: 321–328, 2003.[CrossRef][ISI][Medline]
 

COUNTERPOINT: INTERLEUKIN-6 DOES NOT HAVE A BENEFICIAL ROLE IN INSULIN SENSITIVITY AND GLUCOSE HOMEOSTASIS

Robert A. Mooney

Department of Pathology and Laboratory Medicine
University of Rochester Medical Center
Rochester, New York

Interleukin (IL)-6 is a pleiotropic cytokine with involvement in such diverse physiological and pathological functions as innate immunity and acute phase response, hematopoiesis, liver regeneration, and repair (1, 26). Evidence also supports a role for IL-6 in glucose metabolism and insulin action, but the nature of this role is controversial. As discussed by Dr. Pedersen and Dr. Febbraio, my Point:Counterpoint colleagues whose research has made major contributions to this field, IL-6 can display beneficial effects in regulating glucose metabolism, particularly in skeletal muscle (8). The important question as I see it, however, is whether IL-6, in pathological conditions, contributes to glucose dysregulation. Although IL-6 may have a benign or beneficial role under certain experimental conditions, I will argue that in its relationship to obesity and insulin resistance, which affects as many as one-third of adults in the United States, the contribution of IL-6 is decidedly detrimental, particularly in the liver.

Recent evidence indicates that obesity, with its associated insulin resistance and Type 2 diabetes, is a chronic inflammatory state (29). Considerable effort is directed at determining the contribution of the cytokines, adipokines, and related factors to the altered glucose homeostasis and insulin resistance of this inflammatory state. Circulating IL-6 levels are two- to fourfold higher in obese, Type 2 diabetics than in nonobese controls (7, 17, 18). Kern et. al (12) reported that plasma IL-6 levels correlate better than TNF-{alpha} with obesity and insulin resistance. Similarly, Bastard et al. (3) reported that adipose tissue IL-6 levels but not TNF-{alpha} or leptin levels correlate with insulin resistance in obese subjects. IL-6 levels in serum and adipose tissue also decrease with weight loss (2). A recent study demonstrated that levels of CRP and IL-6 correlate with both insulin resistance and obesity and predict the development of Type 2 diabetes (19). Adipose tissue makes an important contribution to circulating IL-6 levels (16), and the liver is a well- characterized target of IL-6. Omental fat is more strongly linked to insulin resistance than non-visceral fat depots (6) and secretes as much as two- to threefold more IL-6 than subcutaneous fat (9). Importantly, venous drainage of omental fat uses the portal venous system, hence potentially having a preferential effect on the liver.

Is IL-6 an active participant in the insulin resistance and altered carbohydrate metabolism of obesity or is this guilt by association? Both in vivo and in vitro evidence is available to address this question. Kanemaki et al. (11) and others (20) reported that IL-6 inhibits insulin-dependent glycogen synthesis and promotes glucose release from isolated primary hepatocytes. Our group has shown that IL-6 impairs insulin receptor signaling in HepG2 cells and primary hepatocytes and confirms that insulin-dependent glycogen synthesis is inhibited by IL-6 (23). Rotter et al. (21) reported that gene transcription of IRS-1, GLUT4, and PPAR-{gamma} decreased in response to chronic IL-6 in 3T3L1 adipocytes. Insulin-dependent glucose transport and IRS-1 tyrosine phosphorylation were also suppressed.

While in vitro investigations have shown direct inhibitory effects of IL-6 on insulin- responsive target cells, in vivo experiments also support such an effect of IL- 6. In rodents, IL-6 injections lead to increased plasma glucose and insulin levels after 90 min and a marked decrease in liver glycogen (25). Additionally, we reported that mice acutely exposed to IL-6 for 90 min have reduced insulin signal transduction in the liver (24). If the objective is to characterize the role of IL-6 in obesity, however, IL-6 levels should be maintained in a chronically elevated state to mimic obesity. To this end, we used implantable osmotic pumps that deliver IL-6 continuously to mice over 5–7 days. Under these conditions, IL-6 produced a hepatic insulin resistance as determined by impaired insulin receptor signal transduction. Interestingly, skeletal muscle response to insulin was unimpaired (15). Using a more acute IL-6 treatment, Kim et al. (13) infused IL-6 for 3 h during a hyperinsulinemic-euglycemic clamp study. Under these conditions, insulin resistance was observed in both the liver and skeletal muscle. Perhaps the latter reflects the higher dose used and the shorter time frame of the study.

To directly address the role of IL-6 in glucose dysregulation of obesity, an IL-6 neutralizing antibody was used to deplete IL-6 in genetically obese Lepob mice (14). Prior to antibody treatment, elevated STAT3 phosphorylation and increased expression of acute phase proteins haptoglobin and fibrinogen were observed in liver and adipose tissue of the obese mice compared with lean controls, consistent with an obesity-associated elevation of endogenous IL-6. Neutralization of IL-6 returned these markers toward levels seen in lean mice. Importantly, insulin receptor signaling increased in the liver but not in adipose tissue in response to IL-6 depletion. Of relevance to our current discussion, depletion of IL-6 increased insulin sensitivity in the obese mice as reflected in a marked improvement in insulin-dependent suppression of endogenous glucose production (14). Cai et al. (4) reported a similar increase in hepatic insulin sensitivity following treatment of a transgenic mouse model of insulin resistance with IL-6 neutralizing antibody. They argue further that the liver can be an important source of IL-6, with steatosis being a potent stimulus for increased production.

Is IL-6 a promoter of insulin sensitivity and glucose utilization as suggested in part by the expertly performed, acute, human studies by Drs. Pedersen, Febbraio, and colleagues, or is IL-6 the antagonist of insulin action as argued in the studies outlined here? What factors may account for the apparent contradictory effects of IL-6 on glucose homeostasis? Chronicity may be one factor. Most human investigations are by necessity limited to several hours. Obesity is a chronic condition, and the role of IL-6 in this condition may require chronic elevations. Chronic, but not acute, exposure to IL-6 causes inhibitory changes in insulin action in 3T3L1 adipocytes (21). Evidence from the liver regeneration field suggests that short-term (1–2 days) IL-6 exposure yields a protective effect, whereas long term (5–7 days) IL-6 exposure is injurious (10). Differences in response to IL-6 between the insulin responsive tissues are also a factor. While skeletal muscle appears to be the major target for the reported beneficial effects of IL-6, Weigert et al. (28) recently confirmed that, in the liver of mice, IL-6 activates two inhibitory mechanisms that are implicated in insulin resistance, marked induction of SOCS-3 and phosphorylation of IRS-1 on serine-307. Interestingly, IL-6 had no appreciable effect on these inhibitory mechanisms in skeletal muscle. Carey et al. (5) recently confirmed the small effect of IL-6 on SOCS-3 expression in muscle. This tissue-specific difference in induction of SOCS-3 may be quite relevant to this current discussion because we and others have linked SOCS-3 to inhibition of insulin receptor signal transduction in the liver (22, 24, 27). Finally, physiological context may play an important role in determining the response to an inflammatory cytokine such as IL-6. In 3T3L1 adipocytes, IL-6 alone had no acute effect and IL-1{alpha} had only a small inhibitory effect on insulin receptor signal transduction (28). Together, however, these two inflammatory cytokines very potently inhibited insulin receptor signaling. Thus, although considerable evidence supports a role for IL-6 in promoting insulin resistance and glucose dysregulation, optimum characterization of this role may require consideration of the synergy between IL-6 and other elements of the proinflammatory milieu.

GRANTS

The author recognizes support from the National Institute of Diabetes and Digestive and Kidney Diseases (Grants DK-38138 and DK-60732) and the American Diabetes Association (7–04-RA-78).

REFERENCES

  1. Akira S, Taga T, Kishimoto T. Interleukin-6 in biology and medicine. Adv Immunol 54: 1–78, 1993.[ISI][Medline]
  2. Bastard JP, Jardel C, Bruckert E, Blondy P, Capeau J, Laville M, Vidal H, Hainque B. Elevated levels of interleukin 6 are reduced in serum and subcutaneous adipose tissue of obese women after weight loss. J Clin Endocrinol Metab 85: 3338–3342, 2000.[Abstract/Free Full Text]
  3. Bastard JP, Maachi M, Van Nhieu JT, Jardel C, Bruckert E, Grimaldi A, Robert JJ, Capeau J, Hainque B. Adipose tissue IL-6 content correlates with resistance to insulin activation of glucose uptake both in vivo and in vitro. J Clin Endocrinol Metab 87: 2084–2089, 2002.[Abstract/Free Full Text]
  4. Cai D, Yuan M, Frantz DF, Melendez PA, Hansen L, Lee J, Shoelson SE. Local and systemic insulin resistance resulting from hepatic activation of IKK-beta and NF-kappaB. Nat Med 11: 183–190, 2005.[CrossRef][ISI][Medline]
  5. Carey AL, Steinberg GR, Macaulay SL, Thomas WG, Holmes AG, Ramm G, Prelovsek O, Hohnen-Behrens C, Watt MJ, James DE, Kemp BE, Pedersen BK, Febbraio MA. Interleukin-6 increases insulin-stimulated glucose disposal in humans and glucose uptake and fatty acid oxidation in vitro via AMP-activated protein kinase. Diabetes 55: 2688–2697, 2006.[Abstract/Free Full Text]
  6. Carey DG, Jenkins AB, Campbell LV, Freund J, Chisholm DJ. Abdominal fat and insulin resistance in normal and overweight women: direct measurements reveal a strong relationship in subjects at both low and high risk of NIDDM. Diabetes 45: 633–638, 1996.[Abstract]
  7. Desfaits AC, Serri O, Renier G. Normalization of plasma lipid peroxides, monocyte adhesion, and tumor necrosis factor-alpha production in NIDDM patients after gliclazide treatment. Diabetes Care 21: 487–493, 1998.[Abstract]
  8. Febbraio MA, Hiscock N, Sacchetti M, Fischer CP, Pedersen BK. Interleukin-6 is a novel factor mediating glucose homeostasis during skeletal muscle contraction. Diabetes 53: 1643–1648, 2004.[Abstract/Free Full Text]
  9. Fried SK, Bunkin DA, Greenberg AS. Omental and subcutaneous adipose tissues of obese subjects release interleukin-6: depot difference and regulation by glucocorticoid. J Clin Endocrinol Metab 83: 847–850, 1998.[Abstract/Free Full Text]
  10. Jin X, Zimmers TA, Perez EA, Pierce RH, Zhang Z, Koniaris LG. Paradoxical effects of short- and long-term interleukin-6 exposure on liver injury and repair. Hepatology 43: 474–484, 2006.[CrossRef][ISI][Medline]
  11. Kanemaki T, Kitade H, Kaibori M, Sakitani K, Hiramatsu Y, Kamiyama Y, Ito S, Okumura T. Interleukin 1beta and interleukin 6, but not tumor necrosis factor alpha, inhibit insulin-stimulated glycogen synthesis in rat hepatocytes. Hepatology 27: 1296–1303, 1998.[CrossRef][ISI][Medline]
  12. Kern PA, Ranganathan S, Li C, Wood L, Ranganathan G. Adipose tissue tumor necrosis factor and interleukin-6 expression in human obesity and insulin resistance. Am J Physiol Endocrinol Metab 280: E745–E751, 2001.[Abstract/Free Full Text]
  13. Kim HJ, Higashimori T, Park SY, Choi H, Dong J, Kim YJ, Noh HL, Cho YR, Cline G, Kim YB, Kim JK. Differential effects of interleukin-6 and -10 on skeletal muscle and liver insulin action in vivo. Diabetes 53: 1060–1067, 2004.[Abstract/Free Full Text]
  14. Klover PJ, Clementi AH, Mooney RA. Interleukin-6 depletion selectively improves hepatic insulin action in obesity. Endocrinology 146: 3417–3427, 2005.[Abstract/Free Full Text]
  15. Klover PJ, Zimmers TA, Koniaris LG, Mooney RA. Chronic exposure to interleukin-6 causes hepatic insulin resistance in mice. Diabetes 52: 2784–2789, 2003.[Abstract/Free Full Text]
  16. Mohamed-Ali V, Goodrick S, Rawesh A, Katz DR, Miles JM, Yudkin JS, Klein S, Coppack SW. Subcutaneous adipose tissue releases interleukin-6, but not tumor necrosis factor-alpha, in vivo. J Clin Endocrinol Metab 82: 4196–4200, 1997.[Abstract/Free Full Text]
  17. Muller S, Martin S, Koenig W, Hanifi-Moghaddam P, Rathmann W, Haastert B, Giani G, Illig T, Thorand B, Kolb H. Impaired glucose tolerance is associated with increased serum concentrations of interleukin 6 and co-regulated acute-phase proteins but not TNF-alpha or its receptors. Diabetologia 45: 805–812, 2002.[CrossRef][ISI][Medline]
  18. Pickup JC, Chusney GD, Thomas SM, Burt D. Plasma interleukin-6, tumour necrosis factor alpha and blood cytokine production in type 2 diabetes. Life Sci 67: 291–300, 2000.[CrossRef][ISI][Medline]
  19. Pradhan AD, Manson JE, Rifai N, Buring JE, Ridker PM. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA 286: 327–334, 2001.[Abstract/Free Full Text]
  20. Ritchie DG. Interleukin 6 stimulates hepatic glucose release from prelabeled glycogen pools. Am J Physiol Endocrinol Metab 258: E57–E64, 1990.[Abstract/Free Full Text]
  21. Rotter V, Nagaev I, Smith U. Interleukin-6 (IL-6) induces insulin resistance in 3T3–L1 adipocytes and is, like IL-8 and tumor necrosis factor-alpha, overexpressed in human fat cells from insulin-resistant subjects. J Biol Chem 278: 45777–45784, 2003.[Abstract/Free Full Text]
  22. Rui L, Yuan M, Frantz D, Shoelson S, White MF. SOCS-1 and SOCS-3 block insulin signaling by ubiquitin-mediated degradation of IRS1 and IRS2. J Biol Chem 277: 42394–42398, 2002.[Abstract/Free Full Text]
  23. Senn JJ, Klover PJ, Nowak IA, Mooney RA. Interleukin-6 induces cellular insulin resistance in hepatocytes. Diabetes 51: 3391–3399, 2002.[Abstract/Free Full Text]
  24. Senn JJ, Klover PJ, Nowak IA, Zimmers TA, Koniaris LG, Furlanetto RW, Mooney RA. Suppressor of cytokine signaling-3 (SOCS-3), a potential mediator of interleukin-6-dependent insulin resistance in hepatocytes. J Biol Chem 278: 13740–13746, 2003.[Abstract/Free Full Text]
  25. Stith RD, Luo J. Endocrine and carbohydrate responses to interleukin-6 in vivo. Circ Shock 44: 210–215, 1994.[ISI][Medline]
  26. Streetz KL, Luedde T, Manns MP, Trautwein C. Interleukin 6 and liver regeneration. Gut 47: 309–312, 2000.[Free Full Text]
  27. Ueki K, Kondo T, Kahn CR. Suppressor of cytokine signaling 1 (SOCS-1) and SOCS-3 cause insulin resistance through inhibition of tyrosine phosphorylation of insulin receptor substrate proteins by discrete mechanisms. Mol Cell Biol 24: 5434–5446, 2004.[Abstract/Free Full Text]
  28. Weigert C, Hennige AM, Lehmann R, Brodbeck K, Baumgartner F, Schauble M, Haring HU, Schleicher ED. Direct cross-talk of interleukin-6 and insulin signal transduction via insulin receptor substrate-1 in skeletal muscle cells. J Biol Chem 281: 7060–7067, 2006.[Abstract/Free Full Text]
  29. Wellen KE, Hotamisligil GS. Inflammation, stress, diabetes. J Clin Invest 115: 1111–1119, 2005.[CrossRef][ISI][Medline]
 

REBUTTAL FROM DRS. PEDERSEN AND FEBBRAIO

We thank Dr. Mooney for presenting his argument in a concise and scholarly fashion and acknowledge the contribution that his work has made to the field (6). We do not question the validity of the work that indicates that IL-6 may induce insulin resistance in some experimental models, but we feel that two critical issues have been neglected by Dr. Mooney. First, Dr. Mooney highlights that IL-6 is "associated" with insulin resistance in humans. However, association does not equate to causality. Dr. Mooney cites studies (1, 3) that show that IL-6 is associated with insulin resistance in humans, but we would also like to point out that, in our hands, IL-6 is strongly associated with obesity but not insulin resistance using the "gold standard" of measuring insulin sensitivity, the hyperinsulinemic euglycemic clamp (2). This suggests that IL-6 may be a consequence rather than a cause of insulin resistance and it is indeed dangerous to confuse the two. Second, notwithstanding the important issue of "chronicity," all of the work that demonstrates a negative effect of chronic IL-6 in vivo, including the elegant work by Dr. Mooney, who has implanted mini osmotic pumps (5) or used IL-6 antibodies (4), has been performed in rodents. In humans, the effect seems opposite. As cited by us in our original Point article (8), blocking IL-6 in patients with rheumatoid arthritis causes hyperglycemia. Moreover, when a neutralizing anti-IL-6 receptor antibody is given to patients with multicentric Castleman disease for up to 60 wk, patients increase their body weight by 10% and become markedly hypertriglyceridemic (7), in perfect concordance with the work of Jansson and coworkers (10), who have examined the metabolic status of the IL-6 knockout mouse. These critical observations in humans (7) argue against the notion that IL-6 antibody treatment would be a favorable outcome for metabolic disease. Finally, as discussed in our original Point article (8), TNF-{alpha} and not IL-6 may indeed be the "sheep in wolf's clothing." In a recent study (9), plasma-IL-6 concentrations were markedly lowered by anti-TNF-{alpha} therapy. This finding that plasma TNF-{alpha} was not elevated despite high levels of IL-6 and that plasma-IL-6 levels decreased in response to anti-TNF-{alpha} therapy supports the notion that TNF-{alpha} may stimulate IL-6 production and consequently IL-1ra and CRP. In line with this, chronically elevated levels of IL-6 are likely to reflect local ongoing TNF-{alpha} production, the real cause of cytokine-induced insulin resistance in humans.

REFERENCES

  1. Bastard JP, Maachi M, Van Nhieu JT, Jardel C, Bruckert E, Grimaldi A, Robert JJ, Capeau J, Hainque B. Adipose tissue IL-6 content correlates with resistance to insulin activation of glucose uptake both in vivo and in vitro. J Clin Endocrinol Metab 87: 2084–2089, 2002.[Abstract/Free Full Text]
  2. Carey AL, Bruce CR, Sacchetti M, Anderson MJ, Olson DB, Saltin B, Hawley JA, Febbraio MA. IL-6 and TNF{alpha} are not elevated in patients with type two diabetes: evidence that plasma IL-6 is related to fat mass and not insulin responsiveness. Diabetologia 47: 1029–1037, 2004.[ISI][Medline]
  3. Kern PA, Ranganathan S, Li C, Wood L, Ranganathan G. Adipose tissue tumor necrosis factor and interleukin-6 expression in human obesity and insulin resistance. Am J Physiol Endocrinol Metab 280: E745–E751, 2001.[Abstract/Free Full Text]
  4. Klover PJ, Clementi AH, Mooney RA. Interleukin-6 depletion selectively improves hepatic insulin action in obesity. Endocrinology 146: 3417–3427, 2005.[Abstract/Free Full Text]
  5. Klover PJ, Zimmers TA, Koniaris LG, Mooney RA. Chronic exposure to interleukin-6 causes hepatic insulin resistance in mice. Diabetes 52: 2784–2789, 2003.[Abstract/Free Full Text]
  6. Mooney RA. Counterpoint: Interleukin-6 does not have a beneficial role in insulin sensitivity and glucose homeostasis. J Appl Physiol. In press.
  7. Nishimoto N, Kanakura Y, Aozasa K, Johkoh T, Nakamura M, Nakano S, Nakano N, Ikeda Y, Sasaki T, Nishioka K, Hara M, Taguchi H, Kimura Y, Kato Y, Asaoku H, Kumagai S, Kodama F, Nakahara H, Hagihara K, Yoshizaki K, Kishimoto T. Humanized anti-interleukin-6 receptor antibody treatment of multicentric Castleman disease. Blood 106: 2627–2632.
  8. Pedersen BK, Febbraio MA. Point: Interleukin-6 does have a beneficial role in insulin sensitivity and glucose homeostasis. J Appl Physiol. In press.
  9. Rosenvinge A, Krogh-Madsen R, Baslund B, Pedersen BK. Insulin resistance in patients with rheumatoid arthritis—effect of anti-TNF-{alpha} therapy. Scand J Rheumatol. In press.
  10. Wallenius V, Wallenius K, Ahren B, Rudling M, Carlsten H, Dickson SL, Ohlsson C, Jansson JO. Interleukin-6-deficient mice develop mature-onset obesity. Nat Med 8: 75–79, 2002.[CrossRef][ISI][Medline]
 

REBUTTAL FROM DR. MOONEY

As anticipated, Drs. Pedersen and Febbraio do not view IL-6 as a bad guy in insulin action. Let's examine their argument. Acute IL-6 infusions in healthy adults have little or no effect on hepatic glucose metabolism while promoting utilization in skeletal muscle. The critical limitation of these infusion studies, however, is that they do not replicate the chronic elevation of IL-6 in obesity-associated insulin resistance. To date, no human studies adequately address chronic effects of IL-6 on insulin action. A polymorphism in the human IL-6 gene promoter at –174 may chronically affect circulating IL-6 and alter risk of insulin resistance and diabetes, but conclusions are conflicting. My colleagues cite one study (8) to support their arguments, but the report actually concludes that the C-174C genotype alone is not associated with diabetic risk. In another recent study, the G-174G genotype was associated with increased plasma IL-6 and reduced insulin sensitivity (2). My colleagues also cite human studies with IL-6 receptor blocking antibodies (1, 4, 9), but the articles actually make no mention of glucose levels. Unfortunately, no clinical studies with these antibodies have analyzed glucose metabolism.

Without definitive human studies, an understanding of the effects of chronic IL-6 must come from animal and in vitro studies. Depletion of circulating IL-6 in obese mice improved hepatic insulin responsiveness but had no effect in lean mice (7). This supports the conclusion that IL-6 is an important mediator of obesity-associated insulin resistance and is more than the marker of obesity that my colleagues contend (3). This is further supported by Kern et al. (6) who demonstrated that circulating IL-6 levels correlate with insulin resistance independent of BMI.

Finally, tissue-specific differences in response to IL-6 may underlie the two faces of IL-6. My colleagues link IL-6-dependent activation of AMP kinase in L6 myotubes to beneficial metabolic effects of IL-6 in skeletal muscle (6). Interestingly, they had questioned in vitro approaches, particularly those using supraphysiological IL-6 concentrations, yet 100 ng/ml IL-6 was used in their study. We have shown IL-6- dependent inhibition of insulin signaling and increased expression of SOCS-3, a potential mediator of insulin resistance, in hepatocytes in response to fivefold less IL-6 (10). Additionally, IL-6 induces little SOCS-3 in myotubes and is not an effective activator of AMP kinase in liver (5). This supports the conclusion that the liver is a major site for IL-6-dependent dysregulation of insulin action while skeletal muscle may not be a target for this effect.

REFERENCES

  1. Atlizumab: anti-IL6 receptor antibody-Chugai, anti-interleukin-6 receptor antibody-Chugai, MRA-Chugai. BioDrugs 17: 369–372, 2003.[CrossRef][ISI][Medline]
  2. Cardellini M, Perego L, D'Adamo M, Marini MA, Procopio C, Hribal ML, Andreozzi F, Frontoni S, Giacomelli M, Paganelli M, Pontiroli AE, Lauro R, Folli F, Sesti G. C-174G polymorphism in the promoter of the interleukin-6 gene is associated with insulin resistance. Diabetes Care 28: 2007–2012, 2005.[Abstract/Free Full Text]
  3. Carey AL, Bruce CR, Sacchetti M, Anderson MJ, Olsen DB, Saltin B, Hawley JA, Febbraio MA. Interleukin-6 and tumor necrosis factor-alpha are not increased in patients with Type 2 diabetes: evidence that plasma interleukin-6 is related to fat mass and not insulin responsiveness. Diabetologia 47: 1029–1037, 2004.[ISI][Medline]
  4. Choy EH, Isenberg DA, Garrood T, Farrow S, Ioannou Y, Bird H, Cheung N, Williams B, Hazleman B, Price R, Yoshizaki K, Nishimoto N, Kishimoto T, Panayi GS. Therapeutic benefit of blocking interleukin-6 activity with an anti-interleukin-6 receptor monoclonal antibody in rheumatoid arthritis: a randomized, double-blind, placebo-controlled, dose-escalation trial. Arthritis Rheum 46: 3143–3150, 2002.[CrossRef][ISI][Medline]
  5. Kelly M, Keller C, Avilucea PR, Keller P, Luo Z, Xiang X, Giralt M, Hidalgo J, Saha AK, Pedersen BK, Ruderman NB. AMPK activity is diminished in tissues of IL-6 knockout mice: the effect of exercise. Biochem Biophys Res Commun 320: 449–454, 2004.[CrossRef][ISI][Medline]
  6. Kern PA, Ranganathan S, Li C, Wood L, Ranganathan G. Adipose tissue tumor necrosis factor and interleukin-6 expression in human obesity and insulin resistance. Am J Physiol Endocrinol Metab 280: E745–E751, 2001.[Abstract/Free Full Text]
  7. Klover PJ, Clementi AH, Mooney RA. Interleukin-6 depletion selectively improves hepatic insulin action in obesity. Endocrinology 146: 3417–3427, 2005.[Abstract/Free Full Text]
  8. Kubaszek A, Pihlajamaki J, Komarovski V, Lindi V, Lindstrom J, Eriksson J, Valle TT, Hamalainen H, Ilanne-Parikka P, Keinanen-Kiukaanniemi S, Tuomilehto J, Uusitupa M, Laakso M. Promoter polymorphisms of the TNF-alpha (G-308A) and IL-6 (C-174G) genes predict the conversion from impaired glucose tolerance to type 2 diabetes: the Finnish Diabetes Prevention Study. Diabetes 52: 1872–1876, 2003.[Abstract/Free Full Text]
  9. Nishimoto N, Yoshizaki K, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T, Hashimoto J, Azuma J, Kishimoto T. Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trial. Arthritis Rheum 50: 1761–1769, 2004.[CrossRef][ISI][Medline]
  10. Senn JJ, Klover PJ, Nowak IA, Mooney RA. Interleukin-6 induces cellular insulin resistance in hepatocytes. Diabetes 51: 3391–3399, 2002.[Abstract/Free Full Text]



This article has been cited by other articles:


Home page
 Proc. Natl. Acad. Sci. USAHome page
H. Ellingsgaard, J. A. Ehses, E. B. Hammar, L. Van Lommel, R. Quintens, G. Martens, J. Kerr-Conte, F. Pattou, T. Berney, D. Pipeleers, et al.
Interleukin-6 regulates pancreatic {alpha}-cell mass expansion
PNAS, September 2, 2008; 105(35): 13163 - 13168.
[Abstract] [Full Text] [PDF]

Home page
 J EndocrinolHome page
A. G Holmes, J. L Mesa, B. A Neill, J. Chung, A. L Carey, G. R Steinberg, B. E Kemp, R. J Southgate, G. I Lancaster, C. R Bruce, et al.
Prolonged interleukin-6 administration enhances glucose tolerance and increases skeletal muscle PPAR{alpha} and UCP2 expression in rats
J. Endocrinol., August 1, 2008; 198(2): 367 - 374.
[Abstract] [Full Text] [PDF]

Home page
 Endocr. Rev.Home page
M. Y. Donath, J. Storling, L. A. Berchtold, N. Billestrup, and T. Mandrup-Poulsen
Cytokines and {beta}-Cell Biology: from Concept to Clinical Translation
Endocr. Rev., May 1, 2008; 29(3): 334 - 350.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Regul. Integr. Comp. Physiol.Home page
Y. Wei, K. Chen, A. T. Whaley-Connell, C. S. Stump, J. A. Ibdah, and J. R. Sowers
Skeletal muscle insulin resistance: role of inflammatory cytokines and reactive oxygen species
Am J Physiol Regulatory Integrative Comp Physiol, March 1, 2008; 294(3): R673 - R680.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
S. Glund, A. Deshmukh, Y. C. Long, T. Moller, H. A. Koistinen, K. Caidahl, J. R. Zierath, and A. Krook
Interleukin-6 Directly Increases Glucose Metabolism in Resting Human Skeletal Muscle
Diabetes, June 1, 2007; 56(6): 1630 - 1637.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Full Text (PDF) Free
Right arrow All Versions of this Article:
102/2/814    most recent
01208.2006v1
Right arrow Submit a response
Right arrow View responses
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (9)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Pedersen, B. K.
Right arrow Articles by Mooney, R. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pedersen, B. K.
Right arrow Articles by Mooney, R. A.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Visit Other APS Journals Online
Copyright © 2007 by the American Physiological Society.